On July 22, 2025, Abivax S.A. announced positive Phase 3 results from its obefazimod trials for ulcerative colitis, reporting a 16.4% improved remission rate with a 50 mg dose. The company also noted a preliminary cash balance of approximately $71.4 million as of June 30, 2025.